SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 26th, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
CONFIDENTIAL CNS Pharmaceuticals, Inc. Attention: Christopher Downs Suite 900 Houston, TX 77027CNS Pharmaceuticals, Inc. • June 26th, 2024 • Pharmaceutical preparations • New York
The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by CNS Pharmaceuticals, Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
SERIES D COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • June 26th, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 27, 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 27, 2029 (the “Termination Date”), but not thereafter, to subscribe for and purchase from CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to [__] shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
